Milestone Pharmaceuticals
MIST
40 hedge funds and large institutions have $39.9M invested in Milestone Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
63% more call options, than puts
Call options by funds: $44K | Put options by funds: $27K
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
2.33% less ownership
Funds ownership: 58.99% → 56.66% (-2.3%)
9% less funds holding
Funds holding: 44 → 40 (-4)
29% less capital invested
Capital invested by funds: $56.4M → $39.9M (-$16.5M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$798K |
| 2 |
AFA
Alta Fundamental Advisers
New York
|
+$462K |
| 3 |
Squarepoint
New York
|
+$87.9K |
| 4 |
LPC
Lion Point Capital
New York
|
+$64.3K |
| 5 |
AI
Atria Investments
Charlotte,
North Carolina
|
+$45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.16M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$895K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$787K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$359K |
| 5 |
ACM
Altium Capital Management
New York
|
-$322K |
MIST Hedge Fund Activity: Q2 2024 in Review
40 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2024, worth a combined $39.9M — down 29% from $56.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MIST and 3 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was BML Capital Management, adding an estimated $798K. The largest seller was Velan Capital Investment Management, exiting entirely with an estimated $1.16M sold.
- 40 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2024, down from 44 in Q1 2024.
- Funds reported $39.9M of Milestone Pharmaceuticals stock for Q2 2024, down 29% quarter-over-quarter.
- 3 funds opened new Milestone Pharmaceuticals positions in Q2 2024 and 6 closed out, a net change of -3 holders.
- The largest Milestone Pharmaceuticals buyer in Q2 2024 was BML Capital Management, an estimated $798K added.
- The largest Milestone Pharmaceuticals seller in Q2 2024 was Velan Capital Investment Management, an estimated $1.16M sold.
Based on aggregated 13F filings for Q2 2024.